Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504142 | 0.91 | POLQ (0.39) | TP53MAPTLMNAGRIN2B | |
| SCHEMBL17504200 | 0.87 | TP53 (0.42) | TP53MAPTLMNA | |
| SCHEMBL17504152 | 0.86 | GRIN2B (0.37) | TP53LMNAGRIN2B | |
| SCHEMBL17504115 | 0.86 | TP53 (0.40) | TP53MAPTLMNAHDAC6 | |
| SCHEMBL17504133 | 0.85 | POLQ (0.41) | TP53 | |
| SCHEMBL17504188 | 0.83 | RAB9A (0.49) | TP53MAPTLMNA | |
| SCHEMBL17504195 | 0.83 | TP53 (0.46) | TP53MAPTLMNAGRIN2B | |
| SCHEMBL17504111 | 0.82 | LMNA (0.43) | TP53MAPTLMNAGRIN2BHDAC6 | |
| SCHEMBL17518417 | 0.79 | TP53 (0.47) | TP53LMNAHDAC6 | |
| SCHEMBL17504108 | 0.78 | LMNA (0.53) | TP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180319-B1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-10-03 | — | — | EP | claimed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | claimed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | claimed |
| EP-3180319-B1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902701-B2 | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3180319-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| WO-2016023877-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023877-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157133-A1 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP3A43, CYP4B1 | TP53 1340/4885MAPT 3041/4885LMNA 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.